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Abstract
Background: Patients with vasospastic (VA) or non vasospastic angina (NVA) without significant coronary stenosis
have a reduced risk of infarction but is unclear whether or not this may be attributable to a lack of prothrombotic
profile - similar to that present in patients with stable coronary artery disease (CAD).
Methods: Plasma levels of von Willebrand factor, total and free tissue factor pathway inhibitor, plasminogen
activator inhibitor-1, and fibrinogen were analyzed in 15 patients with stable VA and 23 with NVA, all with
vasoconstrictive response to acetylcholine although with different severity. Results were compared with those of 20
age-matched controls and 10 patients with CAD.
Results: Plasma levels of von Willebrand factor in patients with VA or NVA were higher than in controls (207 ± 62
and 203 ± 69% vs 121 ± 38%, p < 0.001) and tended to be lower than in CAD patients (264 ± 65, p = 0.145). They
also presented higher total tissue factor pathway inhibitor (123 ± 18 and 111 ± 25 vs 88 ± 14, ng/ml p < 0.001)
and plasminogen activator inhibitor-1 levels than controls (51 ± 30 and 52 ± 31% vs 19 ± 9 ng/ml, p < 0.001) and
similar to CAD patients (134 ± 23 and 62 ± 31, respectively, ns). Moreover, free tissue factor pathway inhibitor
plasma levels were lower than controls (18 ± 5 and 17 ± 5 vs 23 ± 8 ng/ml, p = 0.002) and similar to CAD patients
(14 ± 5, ns). Despite this prothrombotic condition none of VA or NVA patients presented a myocardial infarction
during a 9 year follow-up, an observation also reported in larger series.
Conclusions: During a stable phase of their disease, patients with VA or NVA present a prothrombotic profile that
might eventually contribute to occurrence of myocardial infarction. The rarity of these events, however, may
suggests that ill defined factors would protect these patients from coronary plaque rupture/fissure.
Background
Endothelial dysfunction has been documented in
patients with angina and non significant coronary steno-
sis, either vasospastic (VA)[1] or non vasospastic (NVA)
- including those with syndrome X [2,3]. Overall,
endothelial dysfunction appears to be a relevant event
for it is often the first step of atherosclerosis [4,5] and
may facilitate coronary thrombosis [6,7]. In fact, patients
with atherosclerosis may present a protrombotic state
characterized by an imbalance in the thrombotic-fibri-
nolytic equilibrium with abnormal plasma levels of von
Willebrand factor (vWF)[8], tissue factor or tissue factor
pathway inhibitor (TFPI)[9-11], plasminogen activator
inhibitor-1 (PAI-1)[12-15] and fibrinogen [14,16]. In
keeping with this, patients with unstable coronary artery
disease and significant coronary stenosis often exhibit
an abnormal coagulation profile which is associated with
increased risk of coronary thrombotic events [14,17].
Nevertheless, VA and NVA patients and for unknown
reasons only rarely develop a myocardial infarction
[18-25]. Thus, the aim of this study was to investigate
whether this reduced incidence of coronary thrombosis
could in part be related to a lack of a pro-thrombotic
profile despite a proven coronary endothelial dysfunc-
tion. Thus, we investigated plasma levels of relevant
* Correspondence: 5751jfb@gmail.com
Unitat Coronària, Àrea del Cor, Laboratori d’Hemostàsia*, Hospital General
Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona. Spain
Figueras et al. Thrombosis Journal 2011, 9:10
http://www.thrombosisjournal.com/content/9/1/10
© 2011 Figueras et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
prothrombotic markers such as vWF, TFPI, PAI-1 and
fibrinogen in stable patients with VA or NV. We com-
pare these levels with those of patients with stable cor-
onary artery disease (CAD) and with normal subjects.
Methods
Patients selection
Thirty eight consecutive patients with typical angina at
rest responsive to sublingual nitroglycerin bsut without
significant coronary stenosis (<50%) were selected from
our chest pain out patient clinic. There were 15 with
documented transient ST elevation and spontaneous
and/or an ergonovine-induced coronary vasospasm cate-
gorized as VA patients, and 23 without ECG changes
during pain and a negative response to ergonovine
(<30% reduction in coronary lumen diameter) categor-
ized as NVA patients. All 38 patients showed endothe-
lial dysfunction manifested by a vasoconstrictive
response to intracoronary acetylcholine which was mild
to moderate (>10% <50% reduction in lumen diameter)
in those with NVA, and severe (vasospasm occluding or
nearly occluding the vessel) in those with VA. VA or
NVA patients were clinically stable but had been hospi-
talized at least once in our institution for their anginal
episodes >12 months prior to entering the study, show-
ing lack of increase in myocardial necrosis markers in
this hospitalization index. Patients with frank hyperten-
sion (=>160 mmHg), left ventricular hypertrophy, bun-
dle branch block, valvular heart disease, previous
myocardial infarction or coronary revascularization pro-
cedures were excluded. Ten consecutive patients with
an uncomplicated myocardial infarction (chest pain
refractory to nitroglycerin, persistent ST segment eleva-
tion and elevated enzymes) => 6 months old and with-
out angina in the follow-up, were selected from our
postmyocardial infarction outpatient clinic and consti-
tuted the CAD group.
Finally, a control group included 20 subjects from the
hospital staff without apparent cardiovascular disease or
major risk factors matched for age with respect to the 3
patient groups.
Protocol
Treatment with nitrates, calcium antagonists, lipid low-
ering drugs or aspirin was discontinued >4 days prior to
blood sampling although sublingual nitroglycerin was
allowed for eventual episodes of chest pain. None of the
patients, however, experienced angina during the 48
hours preceding blood sampling.
Coronary angiography was assessed by quantitative
analysis (Automated coronary analysis, by Philips) by
two observers unaware of the patient’s condition. They
evaluated the number of main epicardial coronary ves-
sels with =>50% stenosis as well as the response to i.v.
ergonovine (sequential doses 0.1 mg at 2 min intervals,
up to 0.85 mg) and intracoronary acetylcholine (20, 50
and 100 micg, at 2 min intervals) in VA and NVA
patients. Ejection fraction was assessed by a contrast left
ventriculogram in all patients except for 4 with CAD in
whom it was assessed by 2D echocardiography. The pro-
tocol was approved by the Hospital Human Ethics Com-
mittee and informed consent was obtained prior to
entering the study.
Blood sampling
Ambulatory venous blood sampling for vWF, total TFPI
(t-TFPI) antigen, free TFPI (f-TFPI) antigen, PAI-1anti-
gen and fibrinogen was performed between 08:30 and
09:30 a.m. in a fasting condition, without vascular com-
pression and with the patient/subject lying in bed for at
least the preceding 30 minutes. They were drawn >6
months after coronary angiography. The first 3 ml of
blood were discarded and 9.0 ml of blood were mixed
with 1.0 ml of sodium citrate (0.13 M) for vWF, t-TFPI,
f-TFPI, PAI-1 and fibrinogen measurements. Samples
were then centrifuged at 3,000 g for 20 minutes at 2-8°
C and the citrated tube was stored at -80°C until
analyzed.
Laboratory methods
Enzyme-linked immunosorbent assays (ELISA) were
used to determine plasma concentrations of vWF, t-
TFPI, f-TFPI (Asserachrom, Diagnostica Stago, Asnieres,
France) and PAI-1 (Tintelize plasminogen activator inhi-
bitor - 1, Biopool, Sweden) whereas fibrinogen plasma
levels were measured by the Von Clauss coagulative
method. Lower limits of detection and the co-efficients
of variation were 3% and 7% for vWF, 11 ng/ml and
6.0% for t-TFPI, 3.12 ng/ml and 7% for f-TFPI, 10 ng/
ml and 5.3% for PAI-1, and 1.18 g/l and 6.4% for fibri-
nogen, respectively.
Statistical Analysis
The Chi-square or the Fisher test were used to compare
categorical variables and the normality of distribution
was assessed using a normal probability plot. Analysis of
variance (ANOVA) was utilized for continuous variables
with normal distribution with post hoc analysis with
Bonferroni correction for multiple comparisons, and the
test of Kruskal-Wallis for continuous variables with
abnormal distribution. The Student T test for unpaired
samples was used for intergroup differences between
one time measurements, and a Pearson’s coefficient cor-
relation analysis between the different parameters and
the risk factors was also carried out. The possible rela-
tionship between medicines taken and levels of labora-
tory parameters was assessed by a univariate analysis.
The analysis was performed with SPSS 13.0, data were
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expressed as percentage or mean mean ± SD and statis-
tical significance was set at p < 0.05.
Results
Demographic and angiographic data
The 4 groups showed a similar age and gender distribution
although VA patients tended to present a lower propor-
tion of women (table 1). Incidence of arterial hypertension
and smoking was comparable in the 3 patients groups,
and total cholesterol and high density lipoprotein levels
were also similar. Patients with VA and NVA were treated
mostly with nitrates and calcium channel blockers whereas
those with CAD were treated more preferentially with
betablockers and aspirin (table 1).
Culprit coronary stenosis =>70% was documented in
5/6 patients with coronary artery disease (83%).
Coagulation factors
vWF plasma levels were higher in VA, NVA, and CAD
patients than in controls
(figure 1), being higher in 93%, 96%, and 100% of
patients, respectively. t-TFPI levels were also higher (fig-
ure 2) being so in 100%, 87% and 100%, respectively). In
contrast, f-TFPI levels were lower in the 3 groups (figure
3), being lower in 67%, 87%, and 90% of patients,
respectively, whereas fibrinogen plasma levels tended to
be higher in the 3 groups than in the control group but
differences were not statistically significant. Moreover,
PAI-1 plasma levels were significantly higher in VA,
NVA and CAD groups than in controls (figure 4), being
higher in 100%, 91% and 100% of patients, respectively,
and were significantly although modestly correlated with
t-TFPI and vWF plasma levels (r:0.329, p = 0.008, and
r:0.299, p = 0.015
Age was correlated with vWF (r:0.365, p = 0.002) and
cholesterol levels with t-TFPI (r:0.449, p = 0.001) and
PAI-1 (r:0.361, p = 0.004). Treatment with nitrates, ACE
inhibitors, beta blockers calcium channel blockers or
aspirin did not seem to influence plasma levels of
hemosthatic parameters since in a univariate analysis
patients treated with these agents showed comparable
levels than those untreated. Patients treated with statins,
however, had higher levels of PAI-1 (68.5 ± 37.4 vs 44.8
± 25 ng/ml, p = 0.030) and lower levels of t-TFPI (114.6
Table 1 Clinical data of control subjects and patients with CAD, VA, or NVA (% and mean ± SD, ANOVA test)
Control (20) CAD (n:10) VA (n:15) NVA (n:23) p
Age, years 54.8 ± 7.5 59.9 ± 8.9 54.5 ± 9.7 55.5 ± 9.1 0.412
Female gender, % 50 40 20 52.2 0.233
Arterial hypertension, % 0 40 53.3 56.5 0.001
Diabetes mellitus, % 0 20 0 0 0.020
Smoking, % 0 40 46.7 26 0.001
Total cholesterol, mg/dl 204 ± 31 234 ± 37 225 ± 38 223 ± 37 0.127
LDL, mg/dl 126 ± 28 158 ± 24 147 ± 23 139 ± 32 0.031
HDL, mg/dl 56 ± 12 46 ± 11 57 ± 16 56 ± 16 0.270
Triglycerides, mg/dl 108 ± 61 169 ± 95 107 ± 33 157 ± 112 0.107
Ejection fraction, % – 55.7 ± 5.5 74.6 ± 4.4 74.1 ± 5.2 0.001
Treatment: (%)
Nitrates 0 0 60 47.8 0.006
Beta blockers 0 70 6.7 26.1 0.003
Calcium channel blockers 0 20 86.7 56.5 0.004
ACE inhibitors 0 40.7 26.7 21.7 0.581
Aspirin 0 100 40 21.7 0.001
Statins 0 60 13.3 26.1 0.049
Figure 1 In all patient groups (NVA, VA and CAD) plasma
levels of vWF levels were significantly higher than in controls
(* = p value of the difference with the control group).
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± 23.8 vs 130.8 ± 20.6 ng/ml, p = 0.031) than untreated
patients likely because of the alluded correlation
between these parameters and cholesterol levels.
Follow-up
During 9 years (108 ± 10 months) there were no cardiac
deaths or myocardial infarction in any of the 38 patients
with VA or NVA. Six VA patients (40%) and 17 with
NVA (74%), however, continued to present angina
although with less frequency and intensity than before
entering the study.
Discussion
Our study documented that patients with stable VA or
NVA had higher levels of vWF, t-TFPI and PAI-1 than
a control group and lower levels of f-TFPI. Moreover,
their values were comparable to patients with asympto-
matic CAD. However, although the association of this
prothrombotic profile with coronary endothelial dys-
function might have facilitated development of coronary
thrombosis, none of our patients presented a myocardial
infarction during an 9 years follow-up which likely sug-
gest the concurrence of protective mechanisms.
vWF
Plasma levels of vWF have not been previously investigated
in VA patients and 3 studies have analyzed vWF levels in
patients with NVA (26-28) with variable results. Thus, Bot-
ker [26] and Kolasinska [27] found vWF levels in NVA
patients similar to a control group but they represented a
different cohort than ours for they had only effort angina
while ours presented rest and, often, mixed angina. In con-
trast, Lin et al. reported increased vWF levels in NVA
patients [28]. These investigators [27,28] included a much
greater proportion of male patients, 64% [27] and >70%
[28], than in our study and than in previous larger NVA
series [20-22] also suggesting a different patient population.
In addition, they did not assess - angiographically - the cor-
onary endothelial function of their patients [26-28].
vWF is a glycoprotein that is critical for platelet adhe-
sion and aggregation to exposed subendothelium, and
plays a major role in thrombus formation [29]. In fact,
increased vWF levels predict adverse cardiac events and
recurrence of myocardial infarction in patients with
acute coronary syndromes [14,17].
Figure 2 Plasma levels of t-TFPI in patients with NVA, VA, or
CAD were higher than in control subjects (* = p value of the
difference with the control group).
Figure 3 In patients with NVA or CAD, f-TFPI levels were
significantly lower than in controls whereas in patients with
VA there was also a similar trend (* = p value of the difference
with the control group).
Figure 4 In all patient groups PAI-1levels were significantly
higher than in controls (* = p value of the difference with the
control group).
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Total and free TFPI
There are no previous studies measuring t-TFPI in
patients with VA or NVA. Thus, our observation of
increased plasma t-TFPI levels in these patients with
respect to a control group constitute a novel finding.
This is of interest since increased TFPI levels have been
reported in patients with unstable angina or acute myo-
cardial infarction [10,11] suggesting a possible causal
role in coronary thrombosis. Indeed, TFPI is the most
important inhibitor of tissue factor which is the princi-
pal determinant of thrombus formation after plaque
rupture [30], and it is thought that increased levels
represent an attempt to balance the procoagulant effects
of increased tissue factor levels [9,31].
Of additional interest, our patients with VA or NVA
showed lower levels of f-TFPI than control subjects.
There is only one study where f-TFPI plasma levels
were investigated in patients with atypical chest pain
and non significant coronary stenosis, and were found
to be similar to patients with stable angina [10]. In this
study, however, patients were no diagnosed of angina
and hence could be different than ours, who presented
with typical spontaneous (rest) angina. Furthermore,
there was no control group and coronary endothelial
function was not assessed [10]. The significance of
abnormal plasma levels of f-TFPI, however, remains
controversial. Thus, while Soejima [10] reported that
increased levels of f-TFPI in patients with unstable
angina were associated with increased risk of unfavor-
able outcomes, Morange demonstrated that reduced
rather than increased f-TFPI plasma level was an inde-
pendent risk factor for myocardial infarction in 10.000
healthy men being an even better predictor when asso-
ciated with increased levels of vWF [32]. Likewise,
reduced f-TFPI levels have been recently linked to intra-
vascular thrombosis in patients with a stroke [33] or
deep vein thombosis [34]. However, the reduced levels
in our VA and NVA were not associated with develop-
ment of coronary thrombosis.
PAI-1
VA patients presented elevated PAI-1 levels and similar
observations were made by Masuda [35] and Yamaguchi
[36]. In contrast, Misumi et al. showed increased PAI-1
levels in VA patients but only following coronary spasm
and not at baseline [37]. Increased PAI-1 levels were
also documented in our NVA patients and, in the only
existing report [27], NVA patients tended also to show
higher plasma levels than a control group, particularly
during exercise, although the differences reached no sta-
tistical significance [27]. This study, however, failed to
provide angiographic evidence of endothelial dysfunction
and had an unusually high proportion of males, 64%
[27].
PAI-1 is released by activated platelets and endothelial
cells and effectively inhibits fibrinolysis [38] by neutra-
lizing tissue plasminogen activator. Increased plasma
levels have been found in patients with unstable angina
or acute myocardial infarction [15,35] and seem to pre-
cede occurrence or recurrence of myocardial infarction
[12-14].
Endothelial dysfunction and myocardial infarction
Despite reduced f-TFPI and increased vWF and PAI-1
levels - all apparent procoagulant factors and markers of
endothelial dysfunction - myocardial infarction did not
occur in our series and has not been a frequent finding
in the follow-up of larger series of patients with VA
without significant stenosis [18,19] or patients with
NVA [20-22]. In some contemporary series, however,
adverse outcomes have been more frequently reported
in NVA patients with proven endothelial dysfunction
[23-25].
Development of a thrombotic coronary occlusion in
CAD patients appears to be independent of the severity
of coronary stenosis since it often occurs in non signifi-
cantly stenosed vessels [8,39] and may even develop
over an endothelial erosion [7]. Thus, since patients
with VA or NVA often share conventional risk factors
and some degree of atherosclerosis with those with
CAD, it is conceivable that further derangements in
their procoagulant profile could supervene during an
unstable phase - intense emotional stress [40] - thereby
enhancing the risk of coronary thrombosis. In this
respect, Buggiardini has recently reported a low inci-
dence of myocardial infarction during a 10 year follow-
up in 42 patients with NVA, 5%, but that was higher in
those with a vasoconstrictive response to acetylcholine
[25]. By and large, however, the remarkably low inci-
dence of thrombotic events despite the correlation
between cholesterol levels and t-TFPI and PAI-1 shown
in our study points to protective mechanisms - possibly
genetically mediated - against development of compli-
cated artheriosclerotic plaques. Indeed, in view of the
reduced use of statins in VA and NVA patients it is
unlikely that cholesterol levels and their positive interac-
tion with prothromboptic factors would decline in the
follow-up. Similarly, the infrequent use of platelet anti-
aggregants would further lower the possibility of a phar-
macological protection.
Limitations
Intracoronary ultrasonographic studies to clarify the
proportion of NVA patients with a completely normal
vascular walls, intimal thickening, or small atherosclero-
tic plaques [41], were not available in our study. Never-
theless, all these patients showed a <50% culprit
stenosis, were well characterized clinically, and had a
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proper assessment of their coronary endothelial dysfunc-
tion. We admit also that the reduced sample size as well
as the lack of measurements of prothrombotic markers
in the follow-up limits the clinical implications with
respect to the risk of coronary thrombotic events
although follow-up was long and larger series had
shown similar results [18-21]. In addition, even though
we attempted to avoid blood sampling during inflamma-
tory processes given their potential interaction with coa-
gulation parameters, we can not totally rule out such an
effect.
Conclusions
Our findings indicate that stable patients with VA or
NVA and angiographically documented coronary
endothelial dysfunction present increased levels of vWF,
t-TFPI and PAI-1, and reduced levels of f-TFPI. They
contribute to the understanding of these poorly defined
syndromes and suggest that this association of coronary
endothelial dysfunction with a prothrombotic state
might eventually facilitate coronary thrombosis, particu-
larly under stressful conditions [40]. However, the lack
of development of myocardial infarction - also seen in
larger series [18-22] - would confirm that this is an unu-
sual complication. Moreover, since less than 1/3 of our
patients were treated with statins and platelet antiaggre-
gants, it is tempting to speculate that they were natu-
rally (genetically) protected from coronary plaque
rupture and subsequent thrombosis.
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